Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 5:47 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 6,680 matching trials from the live ClinicalTrials.gov search.

Filters: Stanford, California Clear all

Conditions: E-cigarette Use
Interventions: Stanford Vaping Prevention curriculum; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 10 Years to 20 Years
Enrollment: 2,779 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Depression, Anxiety, Stress Disorders, Post-Traumatic
Interventions: Life skills and self-defense training; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 21 Years to 65 Years · Female only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Stanford, California

Conditions: Myelodysplastic Syndromes (MDS), Beta-thalassemia, Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis
Interventions: Luspatercept; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 665 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 12
States / cities: Los Angeles, California • Oakland, California • Stanford, California + 9 more

Conditions: Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis
Interventions: Not listed
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Stanford, California

Conditions: Congestive Heart Failure
Interventions: ezCVP measurement; Device
Lead sponsor: Nihon Kohden; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 2
States / cities: Palo Alto, California • Stanford, California

Conditions: Pyruvate Kinase Deficiency
Interventions: RP-L301; Biological
Lead sponsor: Rocket Pharmaceuticals Inc.; Industry
Eligibility: 8 Years to 55 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Parkinson Disease
Interventions: Vibrotactile coordinated reset; Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Stanford, California

Conditions: Coronary Artery Disease
Interventions: Not listed
Lead sponsor: CoreAalst BV; Industry
Eligibility: 21 Years and older
Enrollment: 888 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: Stanford, California • Decatur, Georgia • Bangor, Maine

Conditions: Greater Trochanter Pain Syndrome, Gluteus Medius Tendinopathy, Gluteus Minimus Tendinopathy
Interventions: Platelet-Rich Plasma Injection, Extracorporeal Shock Wave Therapy; Biological · Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Redwood City, California

Conditions: Solid Tumors Harboring NTRK Fusion
Interventions: BAY2757556 (Larotrectinib, Vitrakvi); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 215 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 18
States / cities: Palo Alto, California • Santa Monica, California • Pembroke Pines, Florida + 13 more

Conditions: Abdominal Aortic Aneurysm, Pararenal Aortic Aneurysm, Thoracoabdominal Aortic Aneurysm
Interventions: GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE Device); Device
Lead sponsor: W.L.Gore & Associates; Industry
Eligibility: 18 Years and older
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2036
U.S. locations: 1
States / cities: Stanford, California

Conditions: Hypophosphatemia, Kidney Transplantation
Interventions: Dipyridamole 75 MG; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Stanford, California

Conditions: Sleep Disorders
Interventions: Low rebound mattress toppers, High rebound mattress toppers; Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 558 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Stanford, California

Conditions: Hodgkin Disease
Interventions: high dose chemo then auto hematopoietic cell transplant; Procedure
Lead sponsor: Stanford University; Other
Eligibility: 4 Weeks to 70 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2005
U.S. locations: 1
States / cities: Stanford, California

Conditions: Acromegaly
Interventions: octreotide capsules, Matching placebo; Drug
Lead sponsor: Chiasma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 19
States / cities: Los Angeles, California • Palo Alto, California • Aurora, Colorado + 13 more

Conditions: Pancreatic Carcinoma
Interventions: WallFlex™ Biliary RX Fully Covered/Uncovered Stent System; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 284 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 1
States / cities: Stanford, California

Conditions: Carcinoma, Non-Small-Cell Lung, Lung Cancer (NSCLC), Lung Neoplasms, Carcinoma, Non-Small-Cell Lung (NSCLC), Lung Disease, Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Non-squamous, Non-small Cell Lung Cancer, Squamous
Interventions: PF-08634404, Chemotherapy Regimen 1, Chemotherapy Regimen 2; Biological · Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 15
States / cities: Huntsville, Alabama • Stanford, California • Athens, Georgia + 7 more

Conditions: Ovarian Cancer
Interventions: catumaxomab; Drug
Lead sponsor: Neovii Biotech; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 12
States / cities: Tucson, Arizona • Stanford, California • Orlando, Florida + 9 more

Conditions: Opiate Dependence, Suicidal Ideation, Depression, Opioid Use, Opioid-Related Disorders, Opioid-use Disorder, Major Depressive Disorder
Interventions: Accelerated intermittent theta-burst stimulation (aiTBS); Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Acute Kidney Injury
Interventions: THR-184, Placebo; Drug
Lead sponsor: Thrasos Innovation, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 452 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 31
States / cities: Birmingham, Alabama • Los Angeles, California • Stanford, California + 26 more

Conditions: Cystic Fibrosis
Interventions: 7% Hypertonic Saline (HS), 0.9% Isotonic Saline (IS); Drug
Lead sponsor: CF Therapeutics Development Network Coordinating Center; Network
Eligibility: 4 Months to 59 Months
Enrollment: 321 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 28
States / cities: Birmingham, Alabama • Phoenix, Arizona • Palo Alto, California + 24 more

Conditions: Cell Transplantation
Interventions: Medical Chart Review, Monitoring Device, Physical Therapy; Other · Device · Procedure
Lead sponsor: Stanford University; Other
Eligibility: Not listed
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Leukemia
Interventions: asparaginase, cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, doxorubicin hydrochloride, mercaptopurine, methotrexate, prednisone, thioguanine, vincristine sulfate; Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Year to 21 Years
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 20
States / cities: Los Angeles, California • Palo Alto, California • San Francisco, California + 16 more

Conditions: Infertility
Interventions: In-vitro fertilization using Eeva; Device
Lead sponsor: Progyny, Inc.; Industry
Eligibility: Female only
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 12
States / cities: Encino, California • Palo Alto, California • Redondo Beach, California + 8 more

Search by objective public record fields.

Evaluation of the Be Vape Free Curriculum of the Tobacco Prevention Toolkit

Self-Defense Training in Women With Trauma

A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

Prospective Validation of Cough, Dyspnea, and Quality of Life Questionnaires in Patients With IPF

Study for the Evaluation of a Non-invasive Hemodynamic Measurement in Heart Failure Patients

Clinical Trial to Evaluate the Efficacy of Gene Therapy for Pyruvate Kinase Deficiency

Vibrotactile Coordinated Reset for the Treatment of Advanced Parkinson's Disease

FAME II-10-year Follow-Up

A Randomized Controlled Trial of Ultrasound-guided Platelet-Rich-Plasma (PRP) Injection Versus Extracorporeal Shock Wave Therapy (ESWT) for Great Trochanter Pain Syndrome (GTPS) With Gluteus Medius or Minimus Tendinopathy

A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors

GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis Post-Approval Study

Evaluation of Dipyridamole in Preventing Post-Transplant Hypophosphatemia in Kidney Transplant Recipients

Effect of High Rebound Mattress Toppers on Sleep and Sleep-Related Symptoms

High Dose Chemotherapy Followed By PBSC Rescue for HD

Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly

Preoperative Biliary Drainage in Resectable Pancreatic or Periampullary Cancer

Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC

Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy

Accelerated Intermittent Theta-Burst Stimulation for Opiate Use Disorder

A Study of THR-184 in Patients at Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)

Infant Study of Inhaled Saline in Cystic Fibrosis

Prescribed Physical Activity in Improving Sleep and Physical Performance in Patients Undergoing Stem Cell Transplant

Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia

Registry Study of Traditional Morphology Grading Combined With Eeva in IVF Treatment